2,051 Shares in Johnson & Johnson (NYSE:JNJ) Purchased by Hager Investment Management Services LLC

Hager Investment Management Services LLC acquired a new stake in shares of Johnson & Johnson (NYSE:JNJ) during the fourth quarter, Holdings Channel reports. The firm acquired 2,051 shares of the company’s stock, valued at approximately $297,000.

A number of other large investors have also recently bought and sold shares of JNJ. Cassia Capital Partners LLC raised its stake in shares of Johnson & Johnson by 59.5% in the fourth quarter. Cassia Capital Partners LLC now owns 5,538 shares of the company’s stock valued at $801,000 after acquiring an additional 2,065 shares during the last quarter. Avitas Wealth Management LLC increased its holdings in shares of Johnson & Johnson by 0.6% in the fourth quarter. Avitas Wealth Management LLC now owns 30,181 shares of the company’s stock valued at $4,365,000 after purchasing an additional 182 shares in the last quarter. Redwood Wealth Management Group LLC raised its position in Johnson & Johnson by 3.2% in the 4th quarter. Redwood Wealth Management Group LLC now owns 4,020 shares of the company’s stock worth $580,000 after purchasing an additional 124 shares during the last quarter. Bay Harbor Wealth Management LLC bought a new position in Johnson & Johnson in the 4th quarter valued at $32,000. Finally, E. Ohman J or Asset Management AB increased its stake in shares of Johnson & Johnson by 12.1% in the 4th quarter. E. Ohman J or Asset Management AB now owns 109,740 shares of the company’s stock valued at $15,871,000 after buying an additional 11,840 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger acquired 1,000 shares of Johnson & Johnson stock in a transaction dated Thursday, December 12th. The stock was bought at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the purchase, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. 0.16% of the stock is owned by insiders.

Johnson & Johnson Trading Down 0.3 %

Shares of NYSE:JNJ opened at $153.10 on Friday. The firm has a market cap of $368.61 billion, a price-to-earnings ratio of 23.02, a PEG ratio of 2.44 and a beta of 0.52. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $168.85. The company’s fifty day simple moving average is $147.46 and its 200 day simple moving average is $156.06.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The company had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22.44 billion. During the same period in the prior year, the firm earned $2.29 earnings per share. Johnson & Johnson’s revenue for the quarter was up 5.3% compared to the same quarter last year. As a group, research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be issued a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.24%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s payout ratio is 74.59%.

Wall Street Analysts Forecast Growth

JNJ has been the topic of several recent research reports. Argus upgraded Johnson & Johnson to a “strong-buy” rating in a report on Friday, January 24th. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 16th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 25th. Barclays upped their target price on shares of Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a research report on Tuesday, January 28th. Finally, Bank of America decreased their price objective on Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a research note on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $170.67.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.